CDK4 6-IN-7, a highly potent and selective orally active inhibitor of CDK4 6, demonstrates impressive inhibition activity with IC50 values of 1.58 nM and 4.09 nM respectively. This compound is particularly valuable for breast cancer research [1].
LSN3106729 hydrochloride, the metabolite of Abemaciclib , is a CDKinhibitor with antitumor activity. LSN3106729 hydrochloride and a CRBN ligand have been used to design PROTAC CDK4 6 degrader[1].